Cross-species BBB-penetrant IV-delivered AAV gene therapy provides broad and robust CNS tau lowering in tauopathy mouse ...

Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its ...

Cancer research in the U.S. doesn't rely on a single institution or funding stream − it's a complex ecosystem made up of ...

Commissioners visit UD-based NIIMBL, where public-private partnerships promote innovation, workforce development ...

Six abstracts accepted for presentation includes post hoc analyses and real-world evidence for ZYMFENTRA® (infliximab-dyyb) Findings reinforce clinical decision-making in long-term management of ...